Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

New Study Offers Insight into Alzheimer’s Disease Research Landscape

Posted on September 9th, 2019 by

The sixth leading cause of death in the U.S., and estimated to affect approximately 45 million people worldwide, Alzheimer’s is a progressive brain disease that causes memory loss and overall mental deterioration. Coinciding with World Alzheimer’s Month, Elsevier just released a report (which you can download here) analyzing Alzheimer’s research spanning the last 50 years in order to present a comprehensive overview of the research landscape for this irreversible condition.

(more…)

Elsevier research will be featured at upcoming Safety Pharmacology Society meeting

Posted on September 4th, 2019 by

Network showing human adverse events that are concordant in one or more species (Source: Matthew Clark & Thomas Steiger-Hartmann, Regulatory Toxicology and Pharmacology, July 2018)

The 2019 Safety Pharmacology Society meeting will be in Barcelona from September 23-26, and the event is bringing together industry professionals to share best practices, enjoy networking opportunities, hear keynote speeches from thought leaders, and learn about hot research topics from experts in the field.

(more…)

Cannibidiol is All the Rage – Is Pharma Getting in on the CBD Craze?

Posted on August 14th, 2019 by

Few substances on earth have been surrounded by more confusion than marijuana. Harmless plant or illicit drug? Medicinal or recreational? Legal or illegal (or partially legal)? And what should we make of all these things associated with marijuana, like hemp and CBD oil?

(more…)

The Beneficial Impacts of Real-World Evidence in Drug Development

Posted on August 1st, 2019 by

Advances in technology, increased investment in digital solutions and the creation of more powerful analytics are all contributing to a growing interest in utilizing real-world evidence (RWE) in drug discovery & development. Following up on my previous post that goes into detail on what RWE is and why the industry is increasingly drawn to it, I now want to discuss its role and impact in the drug development life cycle.

(more…)

  1. 1
  2. 2
  3. 3
  4. …
  5. 72